Justin Tremain

Career chronology

• Since 2020-12-01: Turaco Gold Limited — Managing Director. Directors and Management (Turaco Directors and Management, Justin Tremain section, lines 32–37); Directors and Management (Justin Tremain; Managing Director)

• Prior career; detailed dates not stated: Prior employers/qualifications listed by issuer — Prior MD of Exore until its Perseus takeover; founding MD of Renaissance until Emerald takeover; 10+ years natural-resources investment banking.. Directors and Management (Turaco Directors and Management, Justin Tremain section, lines 32–37)

• Founded June 2010; MD until Emerald takeover November 2016: Renaissance Minerals — Founder and Managing Director; later Executive Director at Emerald. Notice of Annual General Meeting / Explanatory Memorandum (Explanatory statement, p.7. Company identifies >1Moz JORC resource and completed feasibility study under his tenure; company outcome only.)

• About two years; company acquired by Perseus September 2020: Exore Resources — Managing Director. Notice of Annual General Meeting / Explanatory Memorandum (Explanatory statement, p.7.)

• Director since 2 October 2020; current: Turaco Gold — Managing Director. Notice of Annual General Meeting / Explanatory Memorandum (Appointment/re-election announcement); Directors and Management (Directors and Management, biography section); Directors and Management (Justin Tremain; Managing Director)

Contributions and company outcomes

Turaco announced a conditional Afema consolidation option and A$120M placement

27-29 October 2026 · issuer reported · medium materiality

On 27 October 2026, Turaco announced an option to acquire Sodim’s remaining 20% Afema interest, subject to shareholder approval for the consideration securities and exercise of the option. On 29 October, the company reported firm commitments for an A$120M placement at A$0.60 per share: A$97.1M unconditional and A$23M subject to shareholder approval. A share purchase plan for up to A$10M was also announced. The transaction and conditional tranche were not complete at the cutoff. Justin Tremain was Managing Director and was quoted in the financing release, but the sources do not establish his individual role in negotiating or structuring the transaction.

Attribution: Role overlaps event; causation unproven. Tremain’s MD role and quoted comment are documented; no source establishes personal authorship, negotiation responsibility or individual causation. Shareholder approval and option exercise remained outstanding.

Relevance: Material capital allocation and financing progress, relevant to MD oversight; transaction completion and future development delivery remained outstanding.

Turaco to Consolidate Afema Ownership and Accelerate Development (pp.1-3; option terms and shareholder-approval condition); Successful A$120M Equity Financing to Consolidate Afema Ownership (pp.1-3; placement commitments, conditional tranche and SPP); Directors and Management (Justin Tremain; Managing Director)

Governance and interests

Turaco retracted non-compliant Afema production target

5 May 2025 · documented · medium materiality

Turaco retracted an earlier 5–6 Mtpa Afema production target, explaining that it had been aspirational, was not disclosed in accordance with ASX Listing Rule 5.16, and had no established technical feasibility or economic viability. This is a company market-communication correction, not a reported regulator enforcement action. Ben Larkin held the combined CFO and Company Secretary role at the time; Justin Tremain was Managing Director. The reviewed material does not establish individual authorship, intent or personal misconduct.

Attribution: Role overlaps event; causation unproven. Both executives held senior roles during the correction; Ben Larkin’s combined finance/company-secretarial office and Justin Tremain’s MD office are role overlaps only. No source reviewed attributes authorship or personal fault to either individual.

Relevance: Relevant to disclosure controls and market communication oversight; the prior target was formally withdrawn before it could be relied on as a supported production plan.

Afema Project Resource Grows 40% to 3.55 Million Ounces Gold (reports retraction and replacement) (lines 11–18 and 34–36)

Suitability for the current role

Public evidence of fit for Managing Director

Current role and prior career as stated by issuer · analyst inference · low materiality

The issuer biography reports: Prior MD of Exore until its Perseus takeover; founding MD of Renaissance until Emerald takeover; 10+ years natural-resources investment banking. Role-fit inference: this experience is relevant to the current Managing Director responsibilities, but issuer biographies are self-reported and do not independently establish personal delivery outcomes.

Attribution: Responsibility not applicable. This is an analyst role-fit judgment based on the cited role and issuer-reported experience; it does not assign personal responsibility for company outcomes.

Relevance: Relevant to the current Managing Director role, with evidence quality constrained by the source scope.

Directors and Management (Turaco Directors and Management, Justin Tremain section, lines 32–37); Directors and Management (Justin Tremain; Managing Director)

Evidence gaps

• Open-web searches do not constitute an exhaustive criminal, sanctions, litigation, regulator, safety or credential check; sources outside the documented search scope may exist.